Provided by Tiger Trade Technology Pte. Ltd.

TransCode Therapeutics Inc.

9.07
-0.4400-4.63%
Post-market: 8.65-0.4246-4.68%19:15 EST
Volume:8.92K
Turnover:81.76K
Market Cap:8.32M
PE:-0.10
High:9.58
Open:9.56
Low:8.69
Close:9.51
52wk High:468.44
52wk Low:6.15
Shares:916.97K
Float Shares:832.40K
Volume Ratio:0.31
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-94.0536
EPS(LYR):-1,317.4218
ROE:-1763.01%
ROA:-232.54%
PB:5.83
PE(LYR):-0.01

Loading ...

Transcode Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing

THOMSON REUTERS
·
Dec 13

TransCode Therapeutics and Quantum Leap Launch Phase 2a Trial for TTX-MC138 in Colorectal Cancer

Reuters
·
Dec 11

Transcode Therapeutics Inc - Phase 2a Trial to Begin in 2026

THOMSON REUTERS
·
Dec 11

BRIEF-Transcode Therapeutics Expands Executive Team With Appointment Of Dr. Michel Janicot As Senior Development Officer

Reuters
·
Nov 17

Transcode Therapeutics Expands Executive Team With Appointment of DR. Michel Janicot as Senior Development Officer

THOMSON REUTERS
·
Nov 17

Press Release: TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Dow Jones
·
Nov 17

TransCode Therapeutics Amends Preferred Stock Designation

TIPRANKS
·
Oct 27

TransCode Therapeutics Updates SEC Filing to Report CVR Agreement Effective Date and Change in Rights Agent

Reuters
·
Oct 18

Transcode Therapeutics Inc - Completes Phase 1a Trial With Ttx-Mc138 in Metastatic Disease at Esmo- SEC Filing

THOMSON REUTERS
·
Oct 14

Transcode Therapeutics Inc - Safety Primary Endpoint Achieved in Phase 1a Trial - SEC Filing

THOMSON REUTERS
·
Oct 14

TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease

Reuters
·
Oct 14

Transcode Therapeutics Issues Correction to Series B Preferred Stock Price in SEC Filing

Reuters
·
Oct 09

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

Benzinga_recent_news
·
Oct 08

TransCode Therapeutics Acquires Polynoma and Secures Investment

TIPRANKS
·
Oct 08

Transcode Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
Oct 08

Transcode Therapeutics to acquire Polynoma

TIPRANKS
·
Oct 08

TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences

Reuters
·
Oct 08

Transcode Therapeutics Inc - Concurrent Equity Investment of $25 Mln From CK Life Sciences Into Transcode

THOMSON REUTERS
·
Oct 08

Transcode Therapeutics Inc: Philippe Calais Appointed as Transcode's Chief Executive Officer and Remains Chairman

THOMSON REUTERS
·
Oct 08

Transcode Therapeutics (Rnaz) Announces the Acquisition of Polynoma and a $25 Million Strategic Financing by a Subsidiary of CK Life Sciences to Form a First-in-Class Unique Immuno-Oncology and Metastatic Prevention Oncology Company

THOMSON REUTERS
·
Oct 08